1. Home
  2. FSP vs CRDF Comparison

FSP vs CRDF Comparison

Compare FSP & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Street Properties Corp.

FSP

Franklin Street Properties Corp.

HOLD

Current Price

$0.43

Market Cap

72.4M

Sector

Real Estate

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$0.84

Market Cap

86.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSP
CRDF
Founded
1981
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.4M
86.8M
IPO Year
2001
2012

Fundamental Metrics

Financial Performance
Metric
FSP
CRDF
Price
$0.43
$0.84
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.63
AVG Volume (30 Days)
340.1K
1.6M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
6.34%
N/A
EPS Growth
15.69
27.37
EPS
N/A
N/A
Revenue
$107,162,000.00
$365,993.00
Revenue This Year
$17.91
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
49.61
52 Week Low
$0.43
$0.80
52 Week High
$1.82
$3.80

Technical Indicators

Market Signals
Indicator
FSP
CRDF
Relative Strength Index (RSI) 31.24 27.54
Support Level N/A N/A
Resistance Level $0.70 $2.03
Average True Range (ATR) 0.02 0.08
MACD -0.00 -0.03
Stochastic Oscillator 1.88 3.63

Price Performance

Historical Comparison
FSP
CRDF

About FSP Franklin Street Properties Corp.

Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: